Impact of Exenatide Injection on Serum Visfatin Level in Patients with Type 2 Diabetes
LI Dan-dan
Abstract：Objective To investigate the effect of Exenatide and Alogliptin on serum visfatin levels and blood glucose concentrations. Methods 80 T2DM patients were randomly divided into two groups: Alogliptin benzoate tablet group (25 mg/d, oral administration, n=40) and Exenatide group (10 μg, subcutaneous injection, n=40). After 12 weeks of treatment, BMI, FPG, HbA1C, FIN, HOMA-IR, CRP, blood pressure, and serum visfatin levels were measured and com-pared between the two groups with those of pretherapy. Results FPG, 2hPG, FIN, P2hIN, HbA1C, HOMA-IR and CRP were markedly improved in both the two group. However, only Exenatide group showed significantly decreased serum Visfatin levels which were positively correlated with BMI, FBG, HbA1C, CRP, FIN, and HOMA-IR (P <0. 05). There was no difference of Visfatin levels in Alogliptin benzoate table group and anlysis showed that HbA1C, FIN, HOMA-IR, and CRP were independent factors associated with visfatin element (P<0. 05). Conclusion In patients with type 2 diabetes, visfatin levels may increase significantly. Exenatide injection can obviously improve insulin resistance and decrease serum Visfatin concentrations. HbA1C, FIN, HOMA-IR, and CRP are independent factors associated with Visfatin element.
Keywords：VisfatinDiabetes mellitustype 2AlogliptinExenatide
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 109-112 )